RT Journal Article
SR Electronic
T1 Ensemble Approaches for Robust and Generalizable Short-Term Forecasts of Dengue Fever. A retrospective and prospective evaluation study in over 180 locations around the world
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.22.24315925
DO 10.1101/2024.10.22.24315925
A1 Wu, Skyler
A1 Meyer, Austin
A1 Clemente, Leonardo
A1 Stolerman, Lucas M.
A1 Lu, Fred
A1 Majumder, Atreyee
A1 Verbeeck, Rudi
A1 Masyn, Serge
A1 Santillana, Mauricio
YR 2024
UL http://medrxiv.org/content/early/2024/10/23/2024.10.22.24315925.abstract
AB Dengue fever, a tropical vector-borne disease, is a leading cause of hospitalization and death in many parts of the world, especially in Asia and Latin America. In places where timely and accurate dengue activity surveillance is available, decision-makers possess valuable information that may allow them to better design and implement public health measures, and improve the allocation of limited public health resources. In addition, robust and reliable near-term forecasts of likely epidemic outcomes may further help anticipate increased demand on healthcare infrastructure and may promote a culture of preparedness. Here, we propose ensemble modeling approaches that combine forecasts produced with a variety of independent mechanistic, statistical, and machine learning component models to forecast reported dengue case counts 1-, 2-, and 3-months ahead of current time at the province level in multiple countries. We assess the ensemble and each component models’ monthly predictive ability in a fully out-of-sample and retrospective fashion, in over 180 locations around the world — all provinces of Brazil, Colombia, Malaysia, Mexico, and Thailand, as well as Iquitos, Peru, and San Juan, Puerto Rico — during at least 2-3 years. Additionally, we evaluate ensemble approaches in a multi-model, real-time, and prospective dengue forecasting platform — where issues of data availability and data completeness introduce important limitations — during an 11-month time period in the years 2022 and 2023. We show that our ensemble modeling approaches lead to reliable and robust prediction estimates when compared to baseline estimates produced with available information at the time of prediction. This can be contrasted with the high variability in the forecasting ability of each individual component model, across locations and time. Furthermore, we find that no individual model leads to optimal and robust predictions across time horizons and locations, and while the ensemble models do not always achieve the best prediction performance in any given location, they consistently provide reliable disease estimates — they rank in the top 3 performing models across locations and time periods — both retrospectively and prospectively.Competing Interest StatementMS has received institutional research funds from the Johnson and Johnson foundation and from Janssen global public health.Funding StatementMS has been funded (in part) by contracts 200-2016-91779 and cooperative agreement CDC-RFA-FT-23-0069 with the Centers for Disease Control and Prevention (CDC). The findings, conclusions, and views expressed are those of the author(s) and do not necessarily represent the official position of the CDC. MS was also partially supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R01GM130668.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that are available for the public health agencies of the relevant countries. In most cases, the data were pulled from processed pdfs.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors